Duration of Therapy with Acetylcholinesterase Inhibitors in Patients with Mild-to-Moderate Alzheimer's Disease as Reported in the Literature

Author： Melik Razan El Dubil Amanda Pound Melanie W.

Publisher： American Society of Consultant Pharmacists

ISSN： 0888-5109

Source： The Consultant Pharmacist, Vol.29, Iss.6, 2014-06, pp. : 400-407

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Is there a rationale for the use of acetylcholinesterase inhibitors in the therapy of Alzheimer's disease?

By Benzi G. Moretti A.

European Journal of Pharmacology, Vol. 346, Iss. 1, 1998-04 ,pp. : 1-13

Elsevier

Access to resources Recommend Favorite

Outcomes of Alzheimer's disease therapy with acetylcholinesterase inhibitors and memantine

By Zemek Filip Drtinova Lucie Nepovimova Eugenie Sepsova Vendula Korabecny Jan Klimes Jiri Kuca Kamil

Expert Opinion on Drug Safety, Vol. 13, Iss. 6, 2014-06 ,pp. : 759-774

Informa Healthcare

Access to resources Recommend Favorite

Rivastigmine Transdermal Patch Skin Tolerability: Results of a 1-Year Clinical Trial in Patients with Mild-to-Moderate Alzheimer's Disease

By Cummings Jeffrey L.

Clinical Drug Investigation, Vol. 30, Iss. 1, 2010-01 ,pp. : 41-49

Adis International

Access to resources Recommend Favorite

Acetylcholinesterase Inhibitors and Sleep Architecture in Patients with Alzheimer's Disease

By Cooke Jana R. Loredo Jose S. Liu Lianqi Marler Matthew Corey-Bloom Jody Fiorentino Lavinia Harrison Tamara Ancoli-Israel Sonia

Drugs & Aging, Vol. 23, Iss. 6, 2006-01 ,pp. : 503-511

Adis International

Access to resources Recommend Favorite

Nicergoline in the Treatment of Mild-to-Moderate Alzheimer's Disease: A European Multicentre Trial

By Winblad B.

Clinical Drug Investigation, Vol. 21, Iss. 9, 2001-09 ,pp. : 621-632

Adis International

Access to resources Recommend Favorite